Camurus CAMX.ST
SwedenHealthcare · BiotechnologyNasdaq Estocolmo · SEK
797.50 SEK (+24.0%)
8 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Camurus AB is a Swedish biopharmaceutical company that develops and commercializes innovative long-acting release medicines for chronic diseases, primarily in the area of opioid dependence and other specialized indications.
Listed on Nasdaq Estocolmo · Symbol CAMX.ST · STO: CAMX · Currency SEK
Key points
from its scores- ✓Very solid balance sheet9.3
- ✓Favourable backdrop8.8
- ✓High-quality business7.5
- ✕Poor share-price trend1.1
- ✕Demanding valuation1.5
AI analysis
bottom line, main risk, context and newsThe quality of the business and the clean balance sheet do not compensate for a valuation that already discounts growth that is not materializing.
Camurus has excellent financial health (net cash of -4.81x EBITDA, liquidity of 10.01) and a solid moat (ROIC of 19.72%, gross margin of 93.07%), but its valuation is very demanding (P/E of 56.80, EV/EBITDA of 41.68) and growth has stalled (revenue +3.90%, earnings -1.50%), which weighs on its attractiveness at current prices.
The main risk is valuation: with a P/E of 56.80 and negative earnings growth (-1.50%), any disappointment in the pipeline or commercialization of its products could trigger a significant correction, as suggested by the negative momentum of -15.24%.
Context and risks
No recent news and no material exposure to current macro factors: the company is a Swedish biopharmaceutical with net cash, so the rise in rates does not significantly affect its balance sheet or valuation. Its business does not depend on commodities or conflict shipping routes.
Is Camurus stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 150% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 56.8 | 26.7 | +112% |
| EV / EBITDA | 41.7 | 14.5 | +188% |
| Price / book | 8.2 | 4.1 | +99% |
| Price / sales | 16.9 | 3.4 | +394% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 1.5 out of 10 (median for Healthcare: 4.7).
Average analyst target: 797.50 SEK, +24.0% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 7.5 (sector 5.5), Growth 4.7 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 56.8
- Forward P/E
- 41.8
- EV / EBITDA
- 41.7
- Price / book
- 8.2
- Price / sales
- 16.9
- Market cap
- 38.3B SEK
- Enterprise value
- 34.3B SEK
Profitability
- ROE
- 15.9%
- ROA
- 10.5%
- ROIC (approx.)
- 19.7%
- Gross margin
- 93.1%
- Operating margin
- 41.7%
- Net margin
- 29.9%
- Free cash flow
- 405.1M SEK
- FCF yield
- 1.1%
- Cash conversion
- 49%
Solvency
- Total debt
- 108.4M SEK
- Net debt
- −4.0B SEK
- Cash
- 4.1B SEK
- EBITDA
- 823.0M SEK
- Net debt / EBITDA
- −4.81
- Debt / equity
- 2.32
- Current ratio
- 10.01
- Quick ratio
- 9.35
Growth
- Revenue growth
- +3.9%
- Earnings growth
- −1.5%
- EPS (TTM)
- 11.32 SEK
- EPS (forward)
- 15.39 SEK
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.43
- Analyst consensus
- Strong buy (8)
- Target price
- 797.50 SEK
- 52-week range
- 430.80 – 710.00
Recent news
All CAMX.ST news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Camurus
Is Camurus stock cheap or expensive?
On P/E and EV / EBITDA, it trades 150% above the Healthcare median on average. Valuation score: 1.5 out of 10 (median for Healthcare: 4.7). Average analyst target: 797.50 SEK, +24.0% versus the price. This is not investment advice.
What score does Camurus get on MeridIAn Screener?
It scores 5.4 out of 10, rank 1,458 of 2,130 (better than 29% of the companies analysed). Its strongest category is Financial health (9.3) and its weakest, Momentum (1.1). Analysis of 08/10/2026.
What is Camurus's P/E ratio?
Its P/E is 56.8: the share price equals 56.8 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 41.8.
How much is Camurus worth on the stock market?
Its market capitalisation is 38.3B SEK and its enterprise value, debt included, is 34.3B SEK.
How much debt does Camurus have?
It has more cash than debt: net cash of 4.0B SEK.
Does Camurus pay a dividend?
It pays no dividend, or almost none.
How has Camurus stock performed over the last year?
It has fallen 6.7% over the last year, excluding dividends. Over the last 52 weeks it has traded between 430.80 and 710.00 SEK. Past performance does not guarantee future results.
What do analysts think of Camurus?
8 analysts cover it; their average recommendation is “Strong buy” and their average target is 797.50 SEK (+24.0% versus the price). It is an estimate, not market data.